The Serpintine Solution

Alexandra Lucas^1,2*, Sriram Ambadapadi¹, Brian Mahon³, Kasinath Viswanathan⁴, Hao Chen⁵, Liying Liu⁶, Erbin Dai⁶, Ganesh Munuswami Ramanujam⁷, Jacek M. Kwiecien⁸, Jordan R Yaron¹, Purushottam Shivaji Narute^1,9, Robert McKenna¹⁰, Shahar Keinan¹¹, Westley Reeves¹², Mark Brantly¹³, Carl Pepine¹⁴ and Grant McFadden¹

¹Biodesign Institute, Center for Personalized Diagnostics, Arizona State University, Tempe AZ, USA

²Saint Josephs Hospital, Dignity Health Phoenix, Phoenix, AZ, USA

³NIH/ NIDDK, Bethesda MD, USA

⁴Zydus Research Centre, Ahmedabad, India

⁵Department of Tumor Surgery, The Second Hospital of Lanzhou University, Lanzhou, Gansu, P.R. China

⁶Beth Israel Deaconess Medical Center, Harvard, Boston, MA, USA

⁷Interdisciplinary Institute of Indian system of Medicine (IIISM), SRM University, Chennai, Tamil Nadu, India

⁸McMaster University, Hamilton, ON, Canada

⁹Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda MD, USA

¹⁰Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL, USA

¹¹Cloud Pharmaceuticals, Durham, North Carolina, USA

¹²Division of Rheumatology, University of Florida, Gainesville, FL, USA

¹³Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Florida, Gainesville, FL, USA

¹⁴Division of Cardiovascular Medicine, University of Florida, Gainesville, FL, USA

^*Corresponding Author: Alexandra Lucas, MD FRCP(C), Director Cardiovascular Fellowship Research, Saint Josephs Hospital, Dignity Health Phoenix, Professor, Biodesign Institute / Arizona State University, Center for Personalized Diagnostics, Room A220D, Tempe, AZ, 727 E Tyler St, 85287, United States, Tel: 352-672-2301 Email:

Editorial